TREVI THERAPEUTICS INC (TRVI) — insider trading
Health Care · NASDAQ
TREVI THERAPEUTICS INC (TRVI) has 22 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 22 (latest 2026-09-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Heffernan Michael Thomas | Director | Option exercise / conversion (derivative) | 21,052 | — | $0 | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas | Director | Option exercise / conversion (derivative) | 18,421 | — | $0 | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas | Director | Open-market sale | 100 | $15.88 | $1.6K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas | Director | Open-market sale | 20,952 | $15.09 | $316.2K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas | Director | Option exercise / conversion | 21,052 | $3.33 | $70.1K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas | Director | Open-market sale | 100 | $15.88 | $1.6K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas | Director | Open-market sale | 18,321 | $15.09 | $276.5K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas | Director | Option exercise / conversion | 18,421 | $3.04 | $56.0K | Form 4 |
| 2026-06-03 | Heffernan Michael Thomas | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-03 | VANLENT ANNE | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-03 | Meeker David P | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-03 | Colangelo Dominick | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-06-03 | Mathers Edward T | Director | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-02-19 | Simon Farrell | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 160,000 | — | $0 | Form 4 |
| 2026-02-19 | GOOD JENNIFER L | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 675,000 | — | $0 | Form 4 |
| 2026-02-19 | SCIASCIA THOMAS | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 85,000 | — | $0 | Form 4 |
| 2026-02-19 | Galletta Christopher | Officer (See Remarks) | Grant / award / vesting (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-02-19 | Cassella James V | Officer (Chief Development Officer) | Grant / award / vesting (derivative) | 215,000 | — | $0 | Form 4 |
| 2025-04-17 | Florence Anthony A. Jr. | 10% owner | Option exercise (in/at-the-money) (derivative) | 1,851,852 | — | $0 | Form 5 |
| 2025-04-17 | Florence Anthony A. Jr. | 10% owner | Option exercise (in/at-the-money) | 1,851,852 | $1.37 | $2.54M | Form 5 |
| 2025-04-17 | SANDELL SCOTT D | 10% owner | Option exercise (in/at-the-money) (derivative) | 1,851,852 | — | $0 | Form 5 |
| 2025-04-17 | SANDELL SCOTT D | 10% owner | Option exercise (in/at-the-money) | 1,851,852 | $1.37 | $2.54M | Form 5 |
Ask the chat about TRVI's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TREVI THERAPEUTICS INC (TRVI).
Last updated 2026-09-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.